Role and prognostic significance of the Ki-67 index in non-Hodgkin's lymphoma

American Journal of Hematology

Volumn 84, Issue 6, 2009, Pages 338-343

  Broyde, Adi ^a,b   Boycov, Olga ^a,b   Strenov, Yulia ^a,b   Okon, Elimelech ^a,b   Shpilberg, Ofer ^a,b   Bairey, Osnat ^a,b  

^a RABIN MEDICAL CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

KI 67 ANTIGEN;

ADULT; ARTICLE; CANCER GRADING; CANCER GROWTH; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; FOLLICULAR LYMPHOMA; HUMAN; IMMUNOHISTOCHEMISTRY; LABORATORY TEST; LARGE CELL LYMPHOMA; MAJOR CLINICAL STUDY; MALE; NONHODGKIN LYMPHOMA; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROGNOSIS;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KI-67 ANTIGEN; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM STAGING; PROGNOSIS; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 66849119383     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.21406     Document Type: Article

References (29)

1. Hernandez J, Kruger JE, Glatstein E. Classification of non-Hodgkin's lymphoma: A proposal. Oncologist 1997;4:235-244. (Pubitemid 27353780)
2. Jaffe ES, Harris NL, Stein H, Vardiman JW, editors. Pathology and Genetics of Tumors of Hematopoietic and Lymphoid Tissues. World Health Organization Classification of Tumors, Vol.3. Lyon, France: IARC Press; 2001.
3. Gribben J, Steward A, Casce L. Clinical manifestations, staging, and treatment of non-Hodgkin lymphoma. In: Hoffman R, Benz E, Shattil S, et al., editors. Hematology: Basic Principles & Practice. Philadelphia: Elsevier; 2005. pp 1397-1419.
4. Brown DC, Gatter KC. Ki-67 protein: The immaculate deception? Histopathology 2002;40:2-11.
5. Elmar E, Gerdes J. The ki-67 protein: Fascinating forms and an unknown function. Exp Cell Res 2000;257:231-237. (Pubitemid 30390473)
6. Scholzen T, Gerdes J. The ki-67 protein: From the known and the unknown. J Cell Physiol 2000;182:311-322. (Pubitemid 30054364)
7. Jerkeman M, Anderson H, Dictor M, et al. Assessment of biological prognostic factors provides clinically relevant information in patients with diffuse large B-cell lymphoma- a Nordic Lymphoma Group study. Ann Hematol 2004;83: 414-419. (Pubitemid 38877961)
8. Vardiman JW, Lister TA, Bloomfield CD. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: Report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997. J Clin Oncol 1999;17:3835-3849.
9. Pich A, Ponti R, Valente G, et al. MIB-1, Ki67, and PCNA scores and DNA flow cytometry in intermediate grade malignant lymphomas. J Clin Pathol 1994;47:18-22. (Pubitemid 24057742)
10. Borre M, Stausbøl-Grøn B, Nerstrøm B, Overgaard J. Immunohistochemical BCL-2 and Ki-67 expression predict survival in prostate cancer patients followed expectantly. Prostate Cancer Prostatic Dis 1998;1:268-275. (Pubitemid 128545875)
11. Keshgegian AA, Cnaan A. Proliferation markers in breast carcinoma. Am J Clin Pathol 1996;106:155.
12. Rudolph P, Lappe T, Hero B, et al. Prognostic significance of the proliferative activity in neuroblastoma. Am J Pathol 1997;150:133-145. (Pubitemid 27027104)
13. Heslin MJ, Cordon-Cardo C, Lewis JJ, et al. Ki-67 detected by MIB-1 predicts distant metastasis and tumor mortality in primary, high-grade extremity soft tissue sarcoma. Cancer 1998;83:490-497. (Pubitemid 28354505)
14. Kalogeraki A, Tzardi M, Panagiotides I, et al. MIB1 (Ki-67) expression in non- Hodgkin's lymphomas. Anticancer Res 1997;17:487-491. (Pubitemid 27116715)
15. Rabenhorst SH, Burini RC, Schmitt FC. Proliferating cell nuclear antigen (PCNA) in non-Hodgkin's lymphomas: Correlation with working formulation and Kiel classification in formalin-fixed paraffin-embedded material. Pathology 1996;28:12-16. (Pubitemid 26072175)
16. Rosewald A, Ott G. Burkitt lymphoma versus diffuse large B-cell lymphoma. Ann Oncol 2008;19(Suppl 4):67-69.
17. Martin AR, Weisenburger DD, Chan WC, et al. Prognostic value of cellular proliferation and histologic grade in follicular lymphoma. Blood 1995;85:3671-3678.
18. Wang SA, Wang L, Hochberg EP, et al. Low histologic grade follicular lymphoma with high proliferation index: Morphologic and clinical features. Am J Surg Pathol 2005;29:1490-1496. (Pubitemid 41513299)
19. Martinez AE, Lin L, Dunphy CH. Grading of follicular lymphoma: Comparison of routine histology with immunohistochemistry. Arch Pathol Lab Med 2007; 131:1084-1088. (Pubitemid 47057897)
20. Pruneri G, Valentini S, Spier CM, et al. Cyclin D3 immunoreactivity in follicular lymphomas in independent of the t(6;14)(p21.1;q32.3) translocation or cyclin D3 gene amplification and is correlated with histologic grade and Ki67 labeling index. Int J Cancer 2004;112:71-77. (Pubitemid 39249493)
21. Grogan TM, Lippman SM, Dahlberg S, et al. Independent prognostic significance of a nuclear proliferation antigen in diffuse large cell lymphomas as determined by the monoclonal antibody Ki-67. Blood 1988;71:1157-1160. (Pubitemid 18111165)
22. Miller TP, Grogan TM, Dahlberg S, et al. Prognostic significance of the Ki-67- associated proliferative antigen in aggressive non-Hodgkin's lymphomas: A prospective Southwest Oncology Group trial. Blood 1994;83:1460-1466. (Pubitemid 24081556)
23. Gerdes J, Stein H, Pileri S, et al. Prognostic relevance of tumor-cell growth fraction in malignant non-Hodgkin's lymphomas. Lancet 1987;2:448-449. (Pubitemid 17131065)
24. Hall PA, Richards MA, Gregory WM, et al. The prognostic value of Ki-67 immunostaining in non-Hodgkin's lymphoma. J Pathol 1988;154:223-235. (Pubitemid 18085645)
25. Winter JN, Andersen J, Variakojis D, et al. Prognostic implications of ploidy and proliferative activity in the diffuse, aggressive non-Hodgkin's lymphomas. Blood 1996;88:3919-3925. (Pubitemid 26383116)
26. de Jong D, Rosenwald A, Chhanabhai M, et al. Immunohistochemical prognostic markers in diffuse large B-cell lymphoma: Validation of tissue microarray as a prerequisite for broad clinical applications - A study from the Lunenberg Lymphoma Biomarker Consortium. J Clin Oncol 2007;25:805-812. (Pubitemid 350002880)
27. Willemze R, Jaffe ES, Burg G, et al. WHO-EORTC classification for cutaneous lymphomas. Blood 2005;105:3768-3785. (Pubitemid 40656118)
28. A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. N Engl J Med 1993;329:987-994
29. Knowles DM. Immunophenotypic markers useful in the diagnosis and clasification of hematopoietic neoplasms. In: Knowles DM, editor. Neoplastic Hematology, 2nd ed. Philadelphia: Lippincott Williams & Wilkins; 2001. pp 173-176.